London Open

Headlines say stocks gain amid corporate deluge as miners rally and all stock picks this week 87% BUY, 7% HOLD and 6% SELL.

1. BUY Zotefoams

Top interesting stock pick this week is BUY Zotefoams by Berenberg with a tip performance of 5%.

Zotefoams is a manufacturer of closed cell crosslinked foams for use in sports, construction, marine, automation, medical equipment and aerospace. Founded in 1921, the company is headquartered in Croydon, with foam manufacturing plants in USA and Poland.

Zotefoams share price launched at 176p in 1995, rose to an all-time high of 682p in 2019 and is today at 412p.

On 22nd January Zotefoams released a trading update in this RNS reporting full year 2025 revenue and adjusted profit expected to be ahead of market expectations with record profitability driven by strong growth in EMEA (notably footwear) and solid performance in North America, while maintaining a strong balance sheet.

In response Berenberg upped its target price from 540p to 590p and reiterated its BUY rating initiated in August 2025.

In Stockomendation three other analysts: Steve Moore with HOLD; Hot Stock Rockets and Canaccord Genuity with BUY. There are no active UK fund manager short positions open.

2. BUY Dotdigital

Second top interesting stock pick this week is BUY DotDigital Group by Canaccord Genuity with a tip performance of 4%.

Dotdigital is an online marketing company listed on the AIM market under the ticker DOTD. It provides email, marketing automation and customer engagement technology.

Dotdigital share price launched at 9p in 2011, rose to an all-time high of 280p in 2021 and is today at 73p.

On 17th January the company released its’ half year results in this RNS reporting a strong first half of the 2026 financial year, with double digit growth in contracted annual recurring revenue from its core customer experience and data platform, solid customer demand across all regions, and confidence that full year results will be in line with market expectations.

The next day the company announced that it has repurchased 180,000 of its ordinary shares in this RNS; at an average price of 70.28 pence per share under its ongoing share buyback programme, increasing the number of shares held in treasury to 5.1 million, reflecting management’s confidence in the business, a strong recurring revenue model, and a well funded balance sheet, making buybacks an efficient use of capital following solid first half trading and after funding the Social Snowball acquisition.

In Stockomendation two analysts with BUY: Peel Hunt and Canaccord Genuity. There are no active short positions.

3. AVOID Dr. Martens

Third interesting stock pick this week is AVOID Dr. Martens by Steve Moore in ShareProphets with a tip performance of 3%.

Dr. Martens, also known as Doc Martens, is a British apparel brand most known for its durable boots with yellow stitching on the sole.

Founded in 1960, it is headquartered in Camden with factories in Northamptonshire and Asia. The company is listed on the London Stock Exchange under the ticker DOCS and is a constituent of the FTSE 250 Index.

Dr. Martens share price launched at 450p in 2021, rose to an all-time high of 503p 4 months later and is today at 68p.

On 27th January the company issued its Q3 trading update in this RNS reporting Q3 group revenue down year-on-year as it deliberately reduced promotions and clearance activity, with direct-to-consumer sales down but wholesale up, and the company expects broadly flat full-year revenue while focusing on improving revenue quality and driving significant profit growth.

In his article Moore questions the positive narrative surrounding the numbers in the update and why the company is still projecting growth for the remainder of 2026 that it looks unlikely to be able to deliver.

In Stockomendation three analysts: Moore with AVOID; Berenberg says BUY and Goldman Sachs is NEUTRAL. No active UK fund manager short positions.

Join Now

Think you can pick stocks? Play the December league UK Share Picking game FREE : uksharepickinggame.co.uk

Disclaimer: The contents of this article should not be considered financial advice. Pricing data correct as at 29th January 2026.